Ticagrelor Administered as Standard Tablet or Orodispersible Formulation
A phase 3 trial registered on ClinicalTrials.gov. The registry status is completed. It enrolled 130 participants.
Also called NCT03822377
- Study
- In this atlas
Overview
- Design
- Interventional study; randomized; single masking; primary purpose treatment
- Phase
- Phase 3
- Enrolled
- 130 participants
- Sponsor
- Registry
-
NCT03822377 -
2018-001790-25
-
- Started
- (actual)
- Primary completion
- (actual)
- Completion
- (actual)
- Results first posted
- Countries
- Italy
- Registry status
- Completed
Technical summary
Registry record NCT03822377. Randomized; single masking; primary purpose treatment. Start 2019-06-27 (actual); primary completion 2020-08-31 (actual). Results posted on 2021-09-08.
The registry's words
Labels as the registry gives them, not rewritten.
- Brief title
- Ticagrelor Administered as Standard Tablet or Orodispersible Formulation
- Acronym
- TASTER
- Condition
- ST Elevation Myocardial Infarction
- Condition
- NSTEMI - Non-ST Segment Elevation MI
- Intervention (Drug)
- Ticagrelor orodispersible tablets
- Intervention (Drug)
- Ticagrelor standard tablets
- Lead sponsor
- Azienda Ospedaliero Universitaria di Sassari
- Collaborator
- AstraZeneca
Record details
- Record id
cardio:ct-nct03822377- Content hash
24bace948360710ad78237ca84189f3b4ed54d46fca5423509c311a967472fd3